SIGMAR1 antibody [N1C3]
GTX115389
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman, Mouse, Rat, Zebra Fish
TargetSIGMAR1
Overview
- SupplierGeneTex
- Product NameSIGMAR1 antibody [N1C3]
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration1.09 mg/ml
- ConjugateUnconjugated
- FormulationLiquid
- Gene ID10280
- Target nameSIGMAR1
- Target descriptionsigma non-opioid intracellular receptor 1
- Target synonymsaging-associated gene 8 protein; ALS16; DSMA2; hSigmaR1; OPRS1; SIG-1R; sigma 1-type opioid receptor; sigma non-opioid intracellular receptor 1; sigma1R; SR31747 binding protein 1; SRBP; SR-BP; SR-BP1
- HostRabbit
- IsotypeIgG
- Protein IDQ99720
- Protein NameSigma non-opioid intracellular receptor 1
- Scientific DescriptionThis gene encodes a receptor protein that interacts with a variety of psychotomimetic drugs, including cocaine and amphetamines. The receptor is believed to play an important role in the cellular functions of various tissues associated with the endocrine, immune, and nervous systems. As indicated by its previous name, opioid receptor sigma 1 (OPRS1), the product of this gene was erroneously thought to function as an opioid receptor; it is now thought to be a non-opioid receptor. Alternative splicing of this gene results in transcript variants encoding distinct isoforms. [provided by RefSeq]
- ReactivityHuman, Mouse, Rat, Zebra Fish
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Novel Pyropheophorbide Phosphatydic Acids Photosensitizer Combined EGFR siRNA Gene Therapy for Head and Neck Cancer Treatment. Yeh CH et al., 2021 Sep 9, PharmaceuticsRead more
- sigma1 receptor ligands control a switch between passive and active threat responses. Rennekamp AJ et al., 2016 Jul, Nat Chem BiolRead more
- Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment. Lecaros RL et al., 2016 Feb, Mol TherRead more
- Nanoparticle delivery of HIF1alpha siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Chen WH et al., 2015 Apr 1, Cancer LettRead more